Vizsgálati helyszín
Institut de Cancérologie de Bourgogne
Dijon, 21000, FranciaországMég nincs intézményhez kötve
- 20futó vizsgálat
- 4lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 25 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis11 vizsgálat
- 2. fázis8 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Toboroz13 vizsgálat
- Fut, nem toboroz7 vizsgálat
- Lezárult2 vizsgálat
- Leállították2 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- UNICANCER5 vizsgálat
- Federation Francophone de Cancerologie Digestive3 vizsgálat
- Hoffmann-La Roche2 vizsgálat
- Aragon Pharmaceuticals, Inc.1 vizsgálat
- Assistance Publique - Hôpitaux de Paris1 vizsgálat
- és még 13
Futó vizsgálatok
Toboroz
Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test
2025-521045-24-00· 3. fázis· Unicancer· Forrás
Toboroz
Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer
NCT07124858· Federation Francophone de Cancerologie Digestive· Forrás
Contact: ARIANE DARUT-JOUVE
Még nem toboroz
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
NCT07150403· 2. fázis· Federation Francophone de Cancerologie Digestive· Forrás
Toboroz
Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
NCT07028125· 4. fázis· Centre Francois Baclesse· Forrás
Fut, nem toboroz
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
NCT06931704· 2. fázis· Nantes University Hospital· Forrás
Toboroz
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
NCT06918002· 3. fázis· Intergroupe Francophone du Myelome· Forrás
Toboroz
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as post transplantation maintenance therapy in patients with newly-diagnosed myeloma
2024-517325-43-00· 2. fázis· Centre Hospitalier Universitaire De Nantes· Forrás
Toboroz
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
NCT06625970· 3. fázis· UNICANCER· Forrás
Toboroz
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· 2. fázis· Centre Hospitalier Universitaire De Dijon· Forrás
Toboroz
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
NCT06561854· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Toboroz
Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer
NCT05874492· Association Francaise pour la Recherche Thermale· Forrás
Contact: Benjamin Schipman
Toboroz
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT05862285· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906· 3. fázis· Bayer· Forrás
Toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585· 3. fázis· AstraZeneca· Forrás
Toboroz
TARGETed Therapy Drug MONITOring in DIGestive Oncology
NCT05443087· UNICANCER· Forrás
Contact: Véronique LORGIS (principal investigator)
Fut, nem toboroz
Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)
NCT03795207· 2. fázis· Institut Cancerologie de l'Ouest· Forrás
Fut, nem toboroz
Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases
NCT03143322· UNICANCER· Forrás
Fut, nem toboroz
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
NCT03774732· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516· 3. fázis· Aragon Pharmaceuticals, Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek